Crohn's disease and ulcerative colitis are not identical
Both are forms of inflammatory bowel disease (IBD), but they affect the gut differently. Ulcerative colitis usually begins in the rectum and is limited mainly to the colon. Crohn's disease can affect any part of the digestive tract, from mouth to anus, and may extend through the intestinal wall. Symptoms may include abdominal pain, diarrhea, bleeding, fatigue, appetite loss, weight loss and episodes of flare and remission.
Why the gut is an intriguing place to study cannabinoids
The intestinal tract includes the enteric nervous system, a large population of immune cells and a microbiome. Components of the endocannabinoid system, including CB1 and CB2, interact with signaling relevant to motility, sensation, secretion and inflammatory responses. This provides a plausible research mechanism; it does not by itself establish an effective IBD medicine.
Why people with IBD use cannabis
The Hebrew source discusses patient surveys in which some people use cannabis for abdominal discomfort, nausea, appetite problems, diarrhea, poor sleep and general quality of life. A 2024 scoping review cited in the source reported cannabis use for symptom control in some surveyed IBD populations. Reported use and perceived benefit are important, but do not prove reduced intestinal inflammation.
The essential distinction: feeling better versus less inflammation
Imagine a person with Crohn's disease who eats more comfortably and feels less pain after cannabis. That benefit may be genuine. Yet THC-related effects on pain perception, appetite or intestinal movement can occur while the intestinal lining remains inflamed. One cannot conclude from symptom relief alone that Crohn's disease has entered remission.
What the Crohn's trials suggest
The source describes small randomized studies in which some clinical activity scores improved. A 2024 synthesis of four randomized Crohn's trials reported improvements in the Crohn's Disease Activity Index (CDAI), but no convincing difference in full remission, quality of life or C-reactive protein (CRP). A lower symptom-weighted score is not the same as proof that bowel inflammation resolved.
Reviews combining Crohn's and colitis
Broader analyses cited in the source found some signals of improvement in patient-reported quality of life or clinical activity, but not consistent improvements in endoscopic activity or inflammatory markers. A 2026 review of THC-containing cannabis products included four randomized trials and four observational studies. The trials gave mixed results and did not establish reliable improvement in the course of IBD; substantial bias limited the observational evidence.
What counts as remission?
Several treatment targets are distinguished. Clinical remission refers to absent or minimal symptoms according to defined criteria. Biochemical remission means inflammatory markers such as CRP or fecal calprotectin meet the relevant target thresholds; a small decrease alone is not enough. Endoscopic remission means inflammation has resolved or is minimal on endoscopy according to a validated score. A person may experience the first while not achieving the other two. Effective IBD management therefore relies on appropriate testing and follow-up.
Why stopping established treatment is risky
If cannabis eases pain or diarrhea while active inflammation continues, discontinuing evidence-based IBD treatment can allow damage to progress unnoticed. Long-term complications can include bleeding, strictures, fistulas in Crohn's disease, hospitalization or surgery. Never infer that a symptom improvement alone makes prescribed anti-inflammatory or immune-targeted treatment unnecessary.
CBD and preclinical anti-inflammatory findings
CBD has been studied in cells and animal models because it can affect signaling pathways related to inflammation. Human trials in IBD have not consistently demonstrated clinical or endoscopic remission, and formulations and dosing vary considerably. The original source does not justify claiming that CBD “treats Crohn's inflammation.”
Bowel motility and appetite
Cannabinoid signaling can change enteric nervous-system activity. Some people may report fewer bowel movements or less urgency, and THC may stimulate appetite. These effects can be welcome when nausea or weight loss is troublesome. They must nevertheless be distinguished from improved nutrient absorption, mucosal healing or suppression of the underlying inflammatory disease.
Crohn's and ulcerative colitis may differ
Some pooled studies have reported more positive signals on clinical activity in Crohn's disease than in ulcerative colitis, but results are not consistent, and objective remission outcomes remain unconvincing. The treatment evidence is not strong enough to recommend cannabinoids as a replacement for established disease control in either condition.
Bottom line
Cannabis may improve certain symptoms for some people living with IBD, while the evidence that it heals bowel inflammation remains insufficient. The clinically important question is whether objective inflammatory disease activity changes—not only how a person feels. Decisions should be made with a gastroenterology team, using appropriate monitoring and medication review.
Scientific sources
- Effectiveness of THC-containing cannabis for inflammatory bowel disease: systematic review. 2026.
Read source ↗ - Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease.
Read source ↗ - Cannabinoids for Inflammatory Bowel Disease: A Scoping Review. Published online 2024; journal issue 2025.
Read source ↗ - Effect of cannabinoids in mild-to-moderate Crohn's disease: systematic review and meta-analysis.
Read source ↗ - Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: systematic review and meta-analysis of randomized controlled trials.
Read source ↗
Ask about individual guidance
Speak with our team to find out whether guidance is appropriate for your situation.
WhatsApp ↗